JP2022547837A5 - - Google Patents

Info

Publication number
JP2022547837A5
JP2022547837A5 JP2022513891A JP2022513891A JP2022547837A5 JP 2022547837 A5 JP2022547837 A5 JP 2022547837A5 JP 2022513891 A JP2022513891 A JP 2022513891A JP 2022513891 A JP2022513891 A JP 2022513891A JP 2022547837 A5 JP2022547837 A5 JP 2022547837A5
Authority
JP
Japan
Prior art keywords
cmsd
itams
modified
itam
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547837A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/112182 external-priority patent/WO2021037222A1/en
Publication of JP2022547837A publication Critical patent/JP2022547837A/ja
Publication of JP2022547837A5 publication Critical patent/JP2022547837A5/ja
Pending legal-status Critical Current

Links

JP2022513891A 2019-08-28 2020-08-28 遺伝子操作されたｔ細胞及びその産生方法 Pending JP2022547837A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/103041 2019-08-28
CN2019103041 2019-08-28
CNPCT/CN2019/125681 2019-12-16
CN2019125681 2019-12-16
PCT/CN2020/112182 WO2021037222A1 (en) 2019-08-28 2020-08-28 Engineered t cells and methods of producing thereof

Publications (2)

Publication Number Publication Date
JP2022547837A JP2022547837A (ja) 2022-11-16
JP2022547837A5 true JP2022547837A5 (https=) 2023-09-01

Family

ID=74683378

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513891A Pending JP2022547837A (ja) 2019-08-28 2020-08-28 遺伝子操作されたｔ細胞及びその産生方法
JP2022513162A Pending JP2022545815A (ja) 2019-08-28 2020-08-28 Ｎｅｆ含有Ｔ細胞及びその産生方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022513162A Pending JP2022545815A (ja) 2019-08-28 2020-08-28 Ｎｅｆ含有Ｔ細胞及びその産生方法

Country Status (12)

Country Link
US (2) US20230085615A2 (https=)
EP (2) EP4022044A4 (https=)
JP (2) JP2022547837A (https=)
KR (2) KR20220066291A (https=)
CN (3) CN114599785A (https=)
AU (2) AU2020339559A1 (https=)
CA (2) CA3152936A1 (https=)
IL (1) IL290946A (https=)
MX (1) MX2022002325A (https=)
TW (2) TW202122574A (https=)
WO (2) WO2021037222A1 (https=)
ZA (1) ZA202202127B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018028647A1 (en) 2016-08-10 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
WO2022174172A1 (en) * 2021-02-15 2022-08-18 H. Lee Moffitt Cancer Center And Research Institute Inc. Customized chimeric antigen receptor polypeptides
WO2023069936A1 (en) * 2021-10-18 2023-04-27 Kite Pharma, Inc. Signaling domains for chimeric antigen receptors
JP2026503179A (ja) * 2022-10-25 2026-01-28 キヴァーナ セラピューティクス インコーポレイテッド 抗ｃｄ１９ ｃａｒ－ｔ細胞療法を使用したループス腎炎の治療方法
WO2024153211A1 (en) * 2023-01-19 2024-07-25 Nanjing Legend Biotech Co., Ltd. Fusion polypeptides for targeted protein degradation and mehtods of use thereof
AU2024239786A1 (en) * 2023-03-20 2025-08-28 Memorial Hospital For Cancer And Allied Diseases Cells and compositions for treating cancer
CN121419987A (zh) * 2023-07-07 2026-01-27 南京传奇生物科技有限公司 蛋白质及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070041A2 (en) * 2004-01-09 2005-08-04 Morehouse School Of Medicine Modulating vaccine against hiv nef protein-induced lymphocyte depletion
US11578115B2 (en) * 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CN108395481B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
CN110520196A (zh) * 2017-04-19 2019-11-29 艾洛基治疗公司 改进的t细胞组合物和方法
CN109306014B (zh) * 2017-07-27 2022-04-12 上海细胞治疗研究院 一种靶向间皮素的嵌合抗原受体修饰t细胞及其用途
US12570958B2 (en) * 2017-12-22 2026-03-10 Cell Design Labs, Inc. Single- and multi-chain chimeric antigen receptors
JP7416695B2 (ja) * 2017-12-29 2024-01-17 メモリアル スローン－ケタリング キャンサー センター 増強されたキメラ抗原受容体およびその使用
US20210023170A1 (en) * 2018-02-12 2021-01-28 University Of Florida Research Foundation, Incorporated Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a

Similar Documents

Publication Publication Date Title
JP2022547837A5 (https=)
JP2022534680A5 (https=)
JP2022545815A5 (https=)
JP2025065142A5 (https=)
TWI817302B (zh) 改良的雙特異性多肽分子
US20050261478A1 (en) Compositions and methods for regulating lymphocyte activation
EP3472205B1 (en) Chimeric antigen receptor
JP2022542543A5 (https=)
JP2023527049A5 (https=)
Steinle et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family
JP2025028239A5 (https=)
JP2020114264A5 (https=)
JP2020511136A5 (https=)
JP2022516496A5 (https=)
US11198737B2 (en) T cell-antigen coupler with Y177 mutation and methods of uses thereof
CN118496374A (zh) 一种抗dll3嵌合抗原受体及其用途
JP2004537952A (ja) 多重特異的結合分子とその使用
JP2022542559A5 (https=)
JP2021532742A5 (https=)
JP2025508343A5 (https=)
JP2025505546A5 (https=)
JP2023524132A5 (https=)
JP2022526720A5 (https=)
JP2024534783A5 (https=)
JP2024507958A5 (https=)